MID Labs

MID Labs is a specialty company focused on developing innovative ophthalmic surgical devices designed for complex vitreoretinal conditions, enhancing surgical precision and efficiency worldwide. Founded in 1981 and headquartered in San Leandro, US, MID Labs specializes in ophthalmic surgical devices. The company has not undergone significant pivots in its strategy and does not have known subsidiaries. The CEO, Kai Chen, has a background in medical device innovation.

MID Labs raised USD 51. 000 mn in funding from Frontline BioVentures, OrbiMed Advisors, SoftBank China Capital, and YuanBio Venture on October 16, 2014. This funding represents the total amount raised by the company to date. MID Labs offers advanced ophthalmic surgical devices including Vitreous Cutters, Bi-Blade Vitreous Cutters, and Single-Step Cannula Insertion Systems.

These products are essential for vitrectomy procedures aimed at preventing blindness from ocular diseases and trauma, and they are distributed in over 30 countries globally, including key markets in Europe, Asia, and South America. The company utilizes a direct sales model, selling its surgical devices primarily to healthcare providers and surgical centers. Transactions are formalized through contracts or agreements, ensuring consistent supply. MID Labs' product line, featuring the Bi-Blade Vitreous Cutters and the Single-Step Cannula Insertion System, is priced in line with industry standards, reflecting the advanced technology embedded in its offerings.

MID Labs plans to leverage the recent funding of USD 51. 000 mn to enhance product development, including upcoming releases of advanced surgical devices expected to be launched in the next two years. The company aims to expand its market presence in Asia and South America by 2025, focusing on increasing distribution channels and partnerships with local healthcare providers.